{"entity":{"id":"nct05208047","kind":"trial","name":"(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors","aka":[],"tldr":"A phase 3 trial testing Bezuclastinib in gastrointestinal stromal tumour, now recruiting.","summary":"(Peak) A Phase 3 Randomised Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumours is a phase 3 interventional study registered as NCT05208047, led by Cogent Biosciences, and recruiting on the registry. Official title: A Phase 3 Randomised, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumours. Planned enrolment is 482 participants (estimated). The study started in 2022-04-14 and primary completion was reached in 2025-09-30. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT05208047","url":"https://clinicaltrials.gov/study/NCT05208047"}],"tags":["ctgov-ingest"],"related":[],"cancers":["gist"],"sections":[],"technologies":[],"targets":[],"drugs":["bezuclastinib"],"companies":["cogent-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Registry status on 22 September 2026: Recruiting (registry record last updated 16 June 2026; primary completion reached 30 September 2025)."],"nct":"NCT05208047","phase":"3","setting":"A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors","sponsor":"Cogent Biosciences","participation":[{"nct":"NCT05208047","source":"https://clinicaltrials.gov/study/NCT05208047","fetchedAt":"2026-10-07T16:53:37.286Z","studySha256":"06eafb9e4c923679408783d22e53c3f413e18c6fea5c90fc20a4b9541b68f121","overallStatus":"RECRUITING","lastUpdatePosted":"2026-06-16","leadSponsor":"Cogent Biosciences, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":482,"enrolmentType":"ESTIMATED","siteCount":126,"recruitingSiteCount":8,"countries":["Argentina","Australia","Brazil","Canada","Chile","Czechia","Denmark","France","Germany","Hong Kong","Hungary","Italy","Mexico","Netherlands","Norway","Poland","South Korea","Spain","Sweden","Taiwan","United Kingdom","United States"]}],"started":"2022-04-14","startedType":"actual","enrolled":482,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05208047/","neighbours":{"cancer":[{"id":"gist","kind":"cancer","name":"Gastrointestinal stromal tumour (GIST)","route":"/cancers/gist/"}],"drug":[{"id":"bezuclastinib","kind":"drug","name":"Bezuclastinib","route":"/drugs/bezuclastinib/"}],"company":[{"id":"cogent-biosciences","kind":"company","name":"Cogent Biosciences","route":"/companies/cogent-biosciences/"}]}}